Results 51 to 60 of about 153,973 (298)

Local attitudes in the treatment of low prognosis head and neck squamous cell carcinoma [PDF]

open access: yes, 2015
The incidence of head and neck carcinoma in Malta is 2.44 per 100,000 population, with 5-year survival rate of 20%. International studies have however shown that head and neck squamous cell carcinoma (HNSCC) carries an average 30% survival rate. The cost
Muscat, Kenneth   +2 more
core  

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

The role of recombinant epidermal growth factor and serotonin in the stimulation of tumor growth in a SCCHN xenograft model [PDF]

open access: yes, 2012
One challenge of squamous cell carcinoma of the head and neck (SCCHN) chemotherapy is a small percentage of tumor cells that arrest in the G0 phase of the cell cycle and are thus not affected by chemotherapy. This could be one reason for tumor recurrence
Arnoldner, Christoph   +6 more
core   +1 more source

Using cell‐free RNA to identify B‐ and T‐cell clonality for diagnosis and monitoring of B‐ and T‐cell neoplasms

open access: yesFEBS Open Bio, EarlyView.
Using peripheral blood for determining B‐cell or T‐cell clonality is more reliable when we use cell‐free RNA (cfRNA) because cells release blood significantly more RNA than DNA. Next‐generation sequencing (NGS) of cfRNA allows us to evaluate fragment cfRNA and evaluate clonality reliably without the need for prior determination of the specific dominant
Adam Albitar   +11 more
wiley   +1 more source

Limited detection of human polyomaviruses in Fanconi anemia related squamous cell carcinoma.

open access: yesPLoS ONE, 2018
Fanconi anemia is a rare genome instability disorder with extreme susceptibility to squamous cell carcinoma of the head and neck and anogenital tract. In patients with this inherited disorder, the risk of head and neck cancer is 800-fold higher than in ...
Tuna Toptan   +11 more
doaj   +1 more source

Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis [PDF]

open access: yes, 2010
Background: Squamous cell carcinoma of the head and neck (SCCHN) are highly invasive tumours with frequent local and distant recurrence. Metastasis formation requires degradation of the extracellular matrix, which is fulfilled by membrane-associated ...
Olivier Gires   +31 more
core   +2 more sources

Development of Patient‐Reported Outcome Measures for Early Systemic Sclerosis Across Disease Subtypes

open access: yesArthritis Care &Research, Accepted Article.
Objective Existing patient‐reported outcome (PRO) measures for systemic sclerosis (SSc) have important limitations, including inadequate coverage of early disease and limited inclusion of diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) subtypes.
George J. Greene   +5 more
wiley   +1 more source

Molecular Characterization of ‘p53 Family Network’ in Human Head and Neck Cancer and Anti-EGFR Therapy [PDF]

open access: yes, 2008
Understanding of p53 family protein (p53, p63 and p73) networks in head and neck squamous cell carcinoma (HNSCC), can positively influence in cancer screening, diagnosis, treatment and prevention.
Sebastian, Sinto
core   +1 more source

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [PDF]

open access: yesNew England Journal of Medicine, 2016
Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ...
R. L. Ferris   +22 more
openaire   +5 more sources

Preclinical models in head and neck squamous cell carcinoma

open access: yesBritish Journal of Cancer, 2022
AbstractHead and neck cancer is the sixth most frequent cancer type. Drug resistance and toxicity are common challenges of the existing therapies, making the development of reliable preclinical models essential for the study of the involved molecular mechanisms as well as for eventual intervention approaches that improve the clinical outcome ...
Patricia Chaves   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy